3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
Standard reconstitution is 2mL of bacteriostatic water into the 80mg vial, giving a 40mg/mL concentration where each U-100 unit (0.01mL) delivers 0.4mg of total blend
They narrowed it down to 36 total studies
Post-Treatment Care: Following your B12 Injection, we provide guidance on post-treatment care
Medical Disclaimer This page is provided for general educational and informational purposes only and does not provide medical advice, diagnosis or treatment
Understanding when each method is appropriate helps optimize your storage strategy for different situations and peptide inventories